Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1551Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data
Oktay Yildirim,Matthias Gottwald,Peter Schüler,Martin C. Michel
Frontiers in Pharmacology.2016;7()
[DOI]
2Extension of the primary care research object model (PCROM) as clinical research information model (CRIM) for the learning healthcare system
Wolfgang Kuchinke,Töresin Karakoyun,Christian Ohmann,Theodoros N Arvanitis,Adel Taweel,Brendan C Delaney,Stuart M Speedie
BMC Medical Informatics and Decision Making.2014;14(1)
[DOI]
3Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required
Amir Lass
Human Reproduction.2017;32(10)2147
[DOI]
4Mechanisms and funding opportunities in genitourinary cancer clinical research
Christopher W. Ryan
Urologic Oncology: Seminars and Original Investigations.2019;37(5)318
[DOI]
5Fellow-Initiated Clinical Trials
Yan Liu,Xuming Dai
Journal of the American College of Cardiology.2015;66(3)324
[DOI]
6Determination of a novel antifibrotic small molecule GDC-3280 in human plasma and urine by liquid chromatography tandem mass spectrometry to support its first-in-human clinical trial
Jianshuang Wang,Michael Van Parys,Lin Pan,Yuan Chen,Dorothy Cheung,Janine McKnight,Dennis Milanowski,Xiao Ding,Brian Dean
Biomedical Chromatography.2019;33(4)e4482
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal